Business Context and Reporting Period
Corvus Pharmaceuticals, Inc. (CRVS) filed a Current Report on Form 8-K dated January 20, 2026. The company is incorporated in Delaware and trades on the Nasdaq Global Market. This filing addresses a specific corporate event regarding a proposed registered underwritten public offering.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the status of a capital raising mechanism.
Material Changes
- Suspension of ATM Offering: On January 20, 2026, the Company notified Jefferies LLC that it has suspended the offering of common stock under its At-The-Market (ATM) Sale Agreement dated August 6, 2024.
- Offering Capacity: The Sale Agreement covered the sale of up to $100 million of common stock (ATM Shares). Prior to this suspension, no shares had been sold, and the full $100 million remained available.
- Agreement Status: While sales are suspended, the Sale Agreement remains in full force and effect. No further sales will occur unless and until a new prospectus supplement or registration statement is filed with the SEC.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Company's anticipated public offering and future expectations. Management highlights that actual results may differ materially due to uncertainties related to market conditions and the completion of the public offering on anticipated terms. The Company disclaims any obligation to update these forward-looking statements. Investors are directed to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, for a detailed description of business risks.
Investor Verification Checklist
- Verify the reason for the suspension of the $100 million ATM offering by reviewing subsequent press releases or management commentary.
- Confirm the current cash position and runway by reviewing the most recent Form 10-Q (ended September 30, 2025) or Form 10-K, as this 8-K does not provide liquidity data.
- Monitor for the filing of a new prospectus supplement or registration statement required to resume sales under the Sale Agreement.
- Review the "Risk Factors" section of the September 30, 2025, 10-Q for details on market condition uncertainties affecting capital raising.